8-K: Compass Therapeutics Announces Second Quarter 2024 Financial Results and Provides Clinical Program Updates

Compass Therapeutics reported its second quarter 2024 financial results, highlighted by the completion of enrollment in a key clinical trial and provided updates on its various drug development programs.

Summary

• Compass Therapeutics announced its second quarter 2024 financial results, reporting a net loss of $13.1 million, or $0.10 per share, compared to a net loss of $11.3 million, or $0.09 per share, for the same period in 2023.
• The company's research and development expenses increased to $11.2 million for the quarter, primarily due to increased clinical costs for the COMPANION-002 trial.
• General and administrative expenses also increased to $4.7 million, due to expenses related to the departure of the CEO.
• Compass ended the quarter with $146 million in cash and marketable securities, which is expected to fund operations into the first quarter of 2027.
• The company completed enrollment of 150 patients in the COMPANION-002 study, a Phase 2/3 trial of CTX-009 in biliary tract cancers, with top-line data expected in the first quarter of 2025.
• An Investigator Sponsored Trial (IST) of CTX-009 in first-line biliary tract cancer patients was approved.
• Preliminary data from the COMPANION-003 trial of CTX-009 in advanced colorectal cancer showed a 5% objective response rate and a median overall survival of 10.2 months.
• Based on these results, the company is evaluating a Phase 2 study of CTX-009 in combination with chemotherapy in second-line DLL4-positive colorectal cancer.
• A Phase 2 monotherapy trial of CTX-471 in patients with a specific biomarker is being planned.
• The combination study of CTX-471 and KEYTRUDA was discontinued due to observed suppression of proinflammatory cytokines.
• The first dosing cohort of the Phase 1 study of CTX-8371 was completed with no dose-limiting toxicities, and the second cohort has been initiated.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials and the strong cash position, but tempered by the increased losses and discontinuation of one combination study.

Positives

• The company has a strong cash position of $146 million, providing a cash runway into the first quarter of 2027.
• Enrollment was completed in the COMPANION-002 trial, a significant milestone for the CTX-009 program.
• Preliminary data from the COMPANION-003 trial showed encouraging efficacy signals for CTX-009 in advanced colorectal cancer.
• The company is advancing multiple clinical programs, including CTX-471 and CTX-8371.
• An Investigator Sponsored Trial (IST) of CTX-009 in first-line biliary tract cancer patients was approved.

Negatives

• The company reported a net loss of $13.1 million for the quarter ended June 30, 2024, an increase from the $11.3 million loss in the same period of 2023.
• Research and development expenses increased by $1.0 million for the quarter, primarily due to increased clinical costs for the COMPANION-002 trial.
• General and administrative expenses increased by $1.6 million for the quarter, due to expenses related to the departure of the CEO.
• The combination study of CTX-471 and KEYTRUDA was discontinued due to observed suppression of proinflammatory cytokines.

Risks

• The company's ability to raise additional funding is crucial to continue its business and product development plans.
• There are inherent uncertainties associated with developing product candidates and operating as a development stage company.
• The company faces competition in the biopharmaceutical industry.
• Clinical trial results may not be positive, and regulatory approvals may not be obtained.
• Market conditions could impact the company's ability to raise capital or commercialize products.

Future Outlook

The company expects its current cash position to fund operations into the first quarter of 2027 and plans to continue advancing its product candidates through clinical development.

Management Comments

• We are excited to report the achievement of an important milestone in our CTX-009 BTC program with the completion of enrollment in COMPANION-002, our Phase 2/3 trial in patients with BTC, said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors.
• We are pleased to confirm the CTX-009 monotherapy Phase 1 data in patients with advanced CRC. There is a significant unmet medical need in this patient population; VEGF-targeted therapies have response rates of 1.5% or less and median overall survival is approximately 7 months.
• Based on these results and the previously reported response data from the Phase 1 trial, we are designing the next study combining CTX-009 with chemotherapy to treat patients with advanced CRC in the second-line setting, selecting patients whose tumors are DLL4-positive.

Industry Context

The company is operating in the competitive oncology biopharmaceutical industry, focusing on developing antibody-based therapeutics. The company's focus on bispecific antibodies and novel targets aligns with current trends in cancer drug development.

Comparison to Industry Standards

• The reported 5% objective response rate for CTX-009 in advanced colorectal cancer is modest compared to some other targeted therapies in the same setting, but the 10.2 month median overall survival is encouraging, especially given the heavily pre-treated patient population.
• VEGF-targeted therapies in third and fourth line colorectal cancer have response rates of 1.5% or less and median overall survival is approximately 7 months, making the CTX-009 results a potential improvement.
• The discontinuation of the CTX-471 and KEYTRUDA combination study due to unexpected cytokine suppression highlights the challenges in developing combination therapies and the importance of understanding drug interactions.
• Companies like Regeneron and Xencor are also developing bispecific antibodies for cancer treatment, making the competitive landscape intense.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the clinical progress and cash runway, but concerned about the increased losses.
• Employees may be affected by the CEO departure and the ongoing restructuring.
• Patients may benefit from the development of new cancer therapies.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company plans to evaluate designs for a Phase 2 study of CTX-009 in combination with chemotherapy in second-line DLL4-positive colorectal cancer.
• A Phase 2 monotherapy trial of CTX-471 in patients with a specific biomarker is being planned.
• The company will continue to advance the Phase 1 study of CTX-8371.
• Top-line data from the COMPANION-002 study is expected in the first quarter of 2025.

Key Dates

Keywords

Compass Therapeutics, CTX-009, CTX-471, CTX-8371, biliary tract cancer, colorectal cancer, clinical trials, bispecific antibody, oncology, biopharmaceutical